Rheumatoid arthritis: Pathogenic mechanisms and therapeutic targets
Numerous novel therapies are in development for rheumatoid arthritis as a consequence of tremendous progress in understanding pathogenic mechanisms and defining relevant disease cells and molecules. Anti-tumour necrosis factor alpha (TNFα) therapies have been particularly successful and set a new st...
| Հիմնական հեղինակներ: | , |
|---|---|
| Ձևաչափ: | Journal article |
| Լեզու: | English |
| Հրապարակվել է: |
2004
|
| Ամփոփում: | Numerous novel therapies are in development for rheumatoid arthritis as a consequence of tremendous progress in understanding pathogenic mechanisms and defining relevant disease cells and molecules. Anti-tumour necrosis factor alpha (TNFα) therapies have been particularly successful and set a new standard for symptom control and attenuation of structural damage to joints. Other potential therapeutic targets across a variety of disease pathways have yet to be fully validated. These include pro-inflammatory cytokines, inflammatory cells and accessory molecules. © 2004 Elsevier Ltd. All rights reserved. |
|---|